0001415889-24-002096.txt : 20240131 0001415889-24-002096.hdr.sgml : 20240131 20240131193433 ACCESSION NUMBER: 0001415889-24-002096 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240129 FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jorgensen Nathan D. CENTRAL INDEX KEY: 0001842523 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39979 FILM NUMBER: 24584573 MAIL ADDRESS: STREET 1: C/O VOR BIOPHARMA INC. STREET 2: 100 CAMBRIDGEPARK DRIVE, SUITE 400 CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vor Biopharma Inc. CENTRAL INDEX KEY: 0001817229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-655-6580 MAIL ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 form4-02012024_120227.xml X0508 4 2024-01-29 0001817229 Vor Biopharma Inc. VOR 0001842523 Jorgensen Nathan D. C/O VOR BIOPHARMA INC. 100 CAMBRIDGEPARK DRIVE, SUITE 101 CAMBRIDGE MA 02140 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2024-01-29 4 A 0 50000 0 A 198449 D Employee Stock Option (right to buy) 2.41 2024-01-29 4 A 0 100000 0 A 2034-01-28 Common Stock 100000 100000 D Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date. Includes 2,802 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan. The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. /s/ Katie Kazem, Attorney-in-Fact 2024-01-31